The Antibody Lab

The Antibody Lab

Vienna, Austria· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $800K

Overview

The Antibody Lab is a private, Vienna-based service provider focused on custom antibody development. Founded in 2007, it serves a global clientele in research, diagnostics, and therapeutic discovery by generating tailored antibodies. As a contract research organization (CRO) in the biologics space, its business model is built on fee-for-service projects, placing it in the 'Revenue Generating' stage. The company's success hinges on its technological capabilities, client relationships, and the sustained demand for high-quality antibody reagents.

AntibodiesBiologicsImmunology

Technology Platform

Integrated platform for custom antibody generation, likely combining hybridoma technology with phage/yeast display libraries for immunization, screening, selection, and engineering of monoclonal antibodies.

Funding History

1
Total raised:$800K
Grant$800K

Opportunities

Growing demand for outsourcing in antibody discovery from both large pharma and virtual biotechs creates a expanding market.
Specialization in complex targets or advanced antibody formats can differentiate its services and command premium pricing.
Strategic partnerships for preferred provider status could ensure a stable project pipeline.

Risk Factors

Faces intense competition from large global CROs and low-cost providers.
Revenue is project-based and can be variable, leading to cash flow uncertainty.
Technological obsolescence is a constant risk if the company fails to adopt new discovery and engineering platforms.

Competitive Landscape

The Antibody Lab operates in a highly competitive CRO market for antibody services. It competes with large international players like GenScript, Bio-Rad, and Abcam's service divisions, as well as numerous specialized SMEs and academic core facilities. Differentiation is achieved through customized service, scientific expertise, and niche capabilities rather than scale.